Comparison of the efficacy of non-invasive USCOM and milrinone in children with severe pneumonia and heart failure and its effect on brain natriuretic peptide levels

doi:10.12092/j.issn.1009-2501.2018.12.015

Abstract

Abstract:

AIM: To observe the clinical effect of non-invasive cardiac output monitoring (USCOM) combined with milrinone in children with severe pneumonia and heart failure and the effect on brain natriuretic peptide levels. METHODS: Seventy-eight children with severe pneumonia and heart failure were randomly divided into experimental group and control group, with 39 cases in each group. The control group received oxygen, anti-infection, anti-heart failure and maintenance of ionic acid-base balance treatment, and was given intravenous infusion of dopamine 5 μg·kg^-1·min^-1 for 24 h. The observation group was given milrinone 0.5 μg·kg^-1·min^-1 based on the control group, intravenous drip, maintained for 24 h. Both groups received 5 d treatment, and the clinical symptoms, signs improvement rate, cardiac function index, inflammatory factors, brain natriuretic peptide levels, and adverse drug reactions were compared between the two groups. RESULTS: After treatment, the irritability disappeared, the wet rales disappeared, the liver retraction and the ruddy rosy improvement rate were higher in the observation group than in the control group (P<0.05). The shortening rate of breast-feeding time in the observation group was lower than that in the control group (P<0.05). After treatment, the HR level in the observation group was lower than that in the control group (P<0.05); the Vpk, FTc and SVI levels in the observation group were higher than those in the observation group. After treatment, the levels of TNF-α, IL-6, IL-8, IL-10 and brain natriuretic peptide in the observation group were lower than those in the control group (P<0.05); No significant difference of nausea and vomiting, diarrhea, blood pressure fluctuation and liver and kidney dysfunction (P>0.05) was observed between the two groups. CONCLUSION: Milrinone can achieve higher short-term curative effect in patients with severe pneumonia and heart failure, which can shorten the clinical symptoms and signs, reduce the incidence of inflammatory factors and adverse drug reactions, and give USCOM monitoring during the treatment to reflect the heart function of patients. Levels help to guide clinical treatment and are worth promoting.

Key words: non-invasive cardiac output monitoring, milrinone, severe pneumonia, heart failure, brain natriuretic peptide, cardiac function level, inflammatory factors, adverse reaction

CLC Number:

WANG Shibiao, WANG Chengyi, WENG Bin, GUO Xiaofeng, LIN Hai. Comparison of the efficacy of non-invasive USCOM and milrinone in children with severe pneumonia and heart failure and its effect on brain natriuretic peptide levels[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1402-1407.

References

［1］韩英，刘涛，耿荣，等.便携式超声心输出量监护仪在肺炎合并心力衰竭患儿心功能状态评价中的意义［J］.中国小儿急救医学，2014，21（5）:285-287.
［2］范娟，陈志颖，陈芃螈，等.超声心输出量监护仪在重症肺炎患儿心功能评价中的应用［J］.中国当代儿科杂志，2016，18（9）:817-820.
［3］Dmytriiev K， Dmytriiev D， Dmytriieva K， et al. Severe pneumonia mortality in pediatric patients is associated with downregulation of Toll--like receptors 2 and 4 on monocytes［J］. Eur Respiratory J， 2016， 48（suppl 60）:PA1304.
［4］许天一，吴萍，王爱玲，等.米力农雾化治疗小儿重症肺炎合并心力衰竭的疗效［J］.山东大学学报:医学版，2016，54（7）:88-90.
［5］周博达，何榕，崔鸣，等.脉搏指示连续心输出量指导下治疗重症肺炎合并心肌梗死和心力衰竭一例［J］.中华心血管病杂志，2016，44（10）:897-898.
［6］孟永胜，何宏蕴，石宏.动态无创肺动脉压力在重症肺炎伴呼吸衰竭监测中的应用分析［J］.重庆医学，2016，45（23）:3273-3275.
［7］Gatera M， Uwimana J， Manzi E， et al. Use of administrative records to assess pneumococcal conjugate vaccine impact on pediatric meningitis and pneumonia hospitalizations in Rwanda［J］. Vaccine， 2016， 34（44）:5321-5328.
［8］刘晓姝，解郑良，滕鸿，等.无创通气治疗肾移植术后重症肺炎致ARDS的疗效观察［J］.中华危重病急救医学，2017，29（11）:994-998.
［9］赵凯，黄磊，黄征，等.连续性血液净化对重症肺炎合并心力衰竭患者血气分析及超声心功能指标的改善作用［J］.中国急救医学，2016，36（12）:1148-1150.
［10］Chisti MJ，Duke T，Salam MA，et al. Impact of diarrhea on the clinical presentation and outcome of severe pneumonia in Bangladeshi children［J］. Pediatr Infect Dis J，2016，35（10）:1161-1162.
［11］周伟. 无创心输出量监测在新生儿中的应用［J］. 中国实用儿科杂志, 2017, 32(5):345-348.
［12］李德原.米力农联合一氧化氮雾化吸入治疗小儿重症肺炎并心力衰竭的临床疗效及预后分析［J］.当代医学，2017，23（6）:45-46.
［13］Saghafianhedengren S，Mathew JL，Hagel E，et al. Assessment of cytokine and chemokine signatures as potential biomarkers of childhood community-acquired pneumonia severity: A nested cohort study in India［J］. Pediatr Infect Dis J，2017，36（1）:102-108.
［14］鲍金芳，翁小斌，季坚卫.米力农治疗小儿先天性心脏病并发重症肺炎及心力衰竭的临床效果［J］.中国生化药物杂志，2017，37（8）:183-184.
［15］Ng DL，Hosani FA，Keating MK，et al. Clinicopathologic, immunohistochemical， and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the United Arab Emirates，April 2014［J］. Am J Pathol,2016,186（3）:652-658.
［16］张振华，王建龙.心理干预联合米力农治疗小儿先天性心脏病并发重症肺炎及心力衰竭的临床探讨［J］.中国生化药物杂志，2017，37（9）:116-117.
［17］黄海霞.米力农治疗小儿先天性心脏病合并重症肺炎及心力衰竭临床观察［J］.中国实用医药，2017，12（36）:92-94.
［18］Omer SB，Clark DR，Aqil AR，et al.Maternal influenza immunization and prevention of severe clinical pneumonia in young infants: Analysis of randomized controlled trials conducted in Nepal, Mali, and South Africa［J］.Pediatr Infect Dis J,2018，37（5）:1.
［19］唐炯，黄德嘉，燕纯伯.米力农联合无创机械通气治疗伴有血压升高的急性心肌梗死后心力衰竭的疗效观察［J］.中西医结合心血管病电子杂志，2016，4（11）:49-50.
［20］钱振华，李茜，马卫星，等.顺尔宁乌司他丁与米力农联合治疗对小儿重症肺炎的影响［J］.浙江临床医学，2017，19（6）:1089-1090.
［21］郑泳森.米力农联合无创呼吸辅助通气治疗充血性心力衰竭的疗效［J］.牡丹江医学院学报，2017，38（3）:60-61.
［22］Alcoba G，Keitel K，Maspoli V，et al. A three-step diagnosis of pediatric pneumonia at the emergency department using clinical predictors， C-reactive protein，and pneumococcal PCR［J］. Eur J Pediatr,2017，176（6）:815.
［23］黄丽华，孙贻霞，年福慧.米力农治疗52例重症肺炎合并心力衰竭婴幼儿的护理体会［J］.安徽医学，2016，37（1）:104-105.
［24］刘东伟，杨勇，程国良，等.急性心肌梗死后心力衰竭患者米力农微量泵入治疗的临床观察［J］.山东医药，2016，56（17）:73-74.
［25］Spichak TV，Yatsyshina SB，Кatosova LК，et al. Is the role of rhinoviruses as causative agents of pediatric community-acquired pneumonia over-estimated［J］ ? Eur J Pediatr,2016,175（12）:1-8.
［26］柳旎，韩旭，王书举.米力农雾化疗法在重症肺部感染并发心力衰竭患儿中的应用效果评价［J］.中华医院感染学杂志，2017，27（21）:5006-5009.
［27］Cannavino CR，Nemeth A，Korczowski B，et al. A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline vs. ceftriaxone［J］. Pediatr Infect Dis J,2016，35（7）:752.
［28］高鹏，寇广亚，武延海.左西孟旦治疗老年顽固性充血性心力衰竭并肾功能不全的疗效评价［J］.实用医学杂志，2016，32（12）:2041-2045.
［29］Silvacosta C， Brito MJ， Pinho MD， et al. Pediatric complicated pneumonia caused by streptococcus pneumoniae serotype 3 in 13-valent pneumococcal conjugate vaccines, Portugal，2010-2015［J］. Emerg Infect Dis, 2018，24（7）:1307-1314.
［30］顾红军，胡志雄，马彩艳.米力农联合地高辛治疗慢性肺源性心脏病的临床疗效及安全性评价［J］.中国临床药理学杂志，2015，31（22）:2190-2192.

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	LI Yang, PAN Weizhong, ZHANG Xiaolu, YU Cuicui. Effects of recovered autologous blood transfusion on immune function and inflammatory response in patients with cesarean section [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 514-524.
[3]	HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382.
[4]	LI Junmin, NIU Hengli, XIE Mingquan, SU Jinlong. Effects of hawthorn flavonoids on atherosclerotic and hyperlipidemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 276-282.
[5]	PENG Yong, FAN Jianfeng, XIONG Xuhua, XIAO Dongping, GAO Zhaobo, ZHENG Chunhua. Effect of iron dextran dispersible tablets on heart failure patients with iron deficiency [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 178-183.
[6]	LI Xinyu, HUANG Xin. State of clinical application of meloxicam [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 189-197.
[7]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[8]	YANG Sheng, WANG Deguo. Effects of sakubatril valsartan combined with dagliflozin in the treatment of patients with HFrEF and the effect on serum cTnⅠ and BNP levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1010-1015.
[9]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[10]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[11]	LIU Ping, QIU Bo, WU Huizhen. Pharmacology and clinical evaluation of vericiguat in the treatment of heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 212-218.
[12]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[13]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[14]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[15]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.